Westhampton Capital LLC Sells 135 Shares of Eli Lilly and Company (NYSE:LLY)

Westhampton Capital LLC trimmed its stake in Eli Lilly and Company (NYSE:LLY) by 6.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,089 shares of the company’s stock after selling 135 shares during the period. Westhampton Capital LLC’s holdings in Eli Lilly and Company were worth $1,851,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. Symphony Financial Ltd. Co. grew its holdings in shares of Eli Lilly and Company by 8.9% during the 3rd quarter. Symphony Financial Ltd. Co. now owns 5,269 shares of the company’s stock worth $4,638,000 after acquiring an additional 432 shares during the period. Blodgett Wealth Advisors LLC grew its position in Eli Lilly and Company by 0.8% during the 3rd quarter. Blodgett Wealth Advisors LLC now owns 4,365 shares of the company’s stock valued at $3,867,000 after purchasing an additional 35 shares during the last quarter. Pegasus Asset Management Inc. increased its position in shares of Eli Lilly and Company by 0.5% during the third quarter. Pegasus Asset Management Inc. now owns 2,848 shares of the company’s stock valued at $2,523,000 after acquiring an additional 15 shares in the last quarter. Eastern Bank raised its stake in shares of Eli Lilly and Company by 145.8% in the third quarter. Eastern Bank now owns 90,057 shares of the company’s stock worth $79,786,000 after purchasing an additional 53,426 shares during the last quarter. Finally, Sequoia Financial Advisors LLC lifted its stake in Eli Lilly and Company by 9.7% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 68,490 shares of the company’s stock valued at $60,678,000 after acquiring an additional 6,069 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Barclays increased their price objective on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 10th. JPMorgan Chase & Co. boosted their price objective on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research report on Friday, September 13th. Morgan Stanley reiterated an “overweight” rating and issued a $1,106.00 price target on shares of Eli Lilly and Company in a report on Tuesday, August 27th. Citigroup began coverage on Eli Lilly and Company in a research report on Friday, September 13th. They set a “buy” rating and a $1,060.00 target price for the company. Finally, BMO Capital Markets upped their price objective on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $1,002.24.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $909.15 on Wednesday. The company has a market capitalization of $864.06 billion, a PE ratio of 133.90, a P/E/G ratio of 2.79 and a beta of 0.42. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. Eli Lilly and Company has a 1 year low of $547.61 and a 1 year high of $972.53. The company has a fifty day moving average of $921.67 and a two-hundred day moving average of $860.45.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. As a group, analysts expect that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.